Drug Trials News for January 2010

Cytheris initiates Phase II clinical trial of CYT107 in HIV patients who fail to achieve optimal immune reconstitution under HAART therapy

The study is designed to confirm safety profile, pharmacokinetics and immunological effects and explore the impact of CYT107 on HIV-specific T-cell responses.
14 January, 2010

Amarin corporation announces first patients enrolled in two Phase III clinical trials assessing AMR101 for the treatment of cardiovascular disease

Lowering triglyceride levels for at-risk patients: first patients enrolled in MARINE and ANCHOR Phase III clinical trials for AMR101.
12 January, 2010

Drug Trials News for January 2010

Drug Trials News Archive

Cytheris initiates Phase II clinical trial of CYT107 in HIV patients who fail to achieve optimal immune reconstitution under HAART therapy Cytheris initiates Phase II clinical trial of CYT107 in HIV patients who fail to achieve optimal immune reconstitution under HAART therapy

Amarin corporation announces first patients enrolled in two Phase III clinical trials assessing AMR101 for the treatment of cardiovascular disease Amarin corporation announces first patients enrolled in two Phase III clinical trials assessing AMR101 for the treatment of cardiovascular disease

Cytheris initiates Phase II clinical trial of CYT107 in HIV patients who fail to achieve optimal immune reconstitution under HAART therapy

Amarin corporation announces first patients enrolled in two Phase III clinical trials assessing AMR101 for the treatment of cardiovascular disease